Back to discover

Protein / target

Leukemia inhibitory factor

Encoded byLIFP15018Homo sapiensSwiss-Prot
Small-molecule tractable
Druggability
Med-Quality Pocket
2
Research papers

Protein at a glance

Biological role

Leukemia inhibitory factor receptor binding

Strongest disease association

Dupuytren Contracture

Via encoding gene LIF · Genetic evidence · score 0.45

Research activity

Emerging research

2 papers · latest 2024

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Functions as a cytokine that binds to the LIF receptor complex.

View complete UniProt function annotation

Functions as a cytokine that binds to the LIF receptor complex (PubMed:11294841, PubMed:14527405, PubMed:36930708). The LIF receptor complex indeed consists of two signaling receptor subunits IL6ST/gp130 and LIFR that transduce the signal into the cell (PubMed:14527405, PubMed:36930708). Functionally, regulates cell self-renewal, differentiation and survival of embryonic stem cells (ESCs) and is crucial for embryonic implantation (By similarity). Mechanistically, ligand binding to LIFR, induces heterodimerization with IL6ST/gp130 activating JAK tyrosine kinases (JAK1 or JAK2 and to a lesser extent TYK2) bound to their intracellular domains (PubMed:11294841). These kinases subsequently phosphorylate IL6ST/gp130 and LIFR (PubMed:11294841). The tyrosine phosphorylated signaling receptors serve in turn as docking sites for recruitment and activation of signal transducers and activators of transcription (STAT3 and to lesser extent STAT1) (PubMed:11294841). In parallel to the activation of the STAT3-pathway, the binding of LIF to the LIF receptor complex leads to the activation of the mitogen-activated protein kinase (MAPK) and the phosphatidylinositol 3-kinase (PI(3)K) pathways (PubMed:11294841). Tyrosine phosphorylation of the p85 subunit of PI(3)K by JAK1 leads to activation of the serine/ threonine kinase AKT (protein kinase B) (PubMed:11294841). PI(3)K-dependent signaling is required for efficient self-renewal of murine ES cells, and regulation of ERK activity is functionally important in this response (By similarity). Moreover, induces tyrosine phosphorylation of PTPN11, that associates with IL6ST/gp130-LIFR, which in turn recruits the p85 regulatory subunit of PI(3)K protein kinase, promoting PI3K-AKT activation, and GRB2-RAS-MAPK signaling (PubMed:11294841)

Subcellular location

Secreted
Domains and Gene Ontology detail (23)

Gene Ontology

  • Ccytosol
  • Cextracellular region
  • Cextracellular space
  • Fcytokine activity
  • Fgrowth factor activity
  • Fleukemia inhibitory factor receptor binding
  • Fsignaling receptor binding
  • Pcell surface receptor signaling pathway via STAT
  • Pimmune response
  • Pleukemia inhibitory factor signaling pathway
  • Pmacrophage differentiation
  • Pnegative regulation of hormone secretion

202 aa · 22 kDa · 2 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell proliferation & survivalGOImmune signallingUniProt · GOTranscriptional regulationUniProt · GO
View supporting evidence

Cell proliferation & survival

  • ·positive regulation of cell population proliferation

Immune signalling

  • ·Functions as a cytokine that binds to the LIF receptor complex (PubMed:11294841, PubMed:…
  • ·cytokine activity
  • ·immune response

Transcriptional regulation

  • ·Functions as a cytokine that binds to the LIF receptor complex (PubMed:11294841, PubMed:…
  • ·positive regulation of transcription by RNA polymerase II

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene LIF

Gene-level evidence surfaced through the gene LIFthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Dupuytren Contracture
0.45Limited support

Genetic evidence dominant · Open Targets 0.27

Alcohol drinking
0.44Limited support

Genetic evidence dominant · Open Targets 0.27

Breast Neoplasms
0.23Preliminary

Literature evidence dominant · Open Targets 0.13 · no direct causal or clinical evidence

Glaucoma, Open-Angle
0.22Preliminary

Genetic evidence dominant · Open Targets 0.13

Glaucoma
0.21Preliminary

Genetic evidence dominant · Open Targets 0.12

View evidence synthesis (5)
Dupuytren ContractureLimited support
0.45
agreement 0.330.57
Genetic100%

Open Targets aggregate 0.27 · 1 independent evidence family

Alcohol drinkingLimited support
0.44
agreement 0.320.56
Genetic100%

Open Targets aggregate 0.27 · 1 independent evidence family

Breast NeoplasmsPreliminary
0.23
agreement 0.040.42
Literature56%RNA expression44%

Open Targets aggregate 0.13 · 2 independent evidence families · no direct causal or clinical evidence

Glaucoma, Open-AnglePreliminary
0.22
agreement 0.080.36
Genetic96%Literature4%

Open Targets aggregate 0.13 · 2 independent evidence families

GlaucomaPreliminary
0.21
agreement 0.070.35
Genetic95%Literature6%

Open Targets aggregate 0.12 · 2 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Dupuytren Contracture0.27
Alcohol drinking0.27
Glaucoma, Open-Angle0.13
Breast Neoplasms0.13
Glaucoma0.12
Neoplasms0.12

Tractability

Small moleculesEmerging

Feasibility evidence (med-quality pocket) — no clinical-stage drug of this modality recorded.

AntibodiesEmerging

Feasibility evidence (go cc high conf and uniprot loc med conf) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (4)
SM · Med-Quality PocketAB · GO CC high confAB · UniProt loc med confAB · UniProt SigP or TMHMM

Raw Open Targets tractability assessment buckets, by modality.

Research activity

2 papers · to 2024

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Korsching S · The Journal of neuroscience : the official journal of the Society for Neuroscience · 1993

Agca S · The FEBS journal · 2024

Recent

The neurotrophic factor concept: a reexamination.

Korsching S · The Journal of neuroscience : the official journal of the Society for Neuroscience · 1993

Europe PMC papers linked directly to this protein.